Efficacy and Safety of Tazbentetol in ALS Participants
ConditionAmyotrophic Lateral Sclerosis
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorSpinogenix
About this trial
The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.
Eligibility criteria
Qualifiers
Age 18-80
ALS TRICALS risk score
Stable dose of standard of care treatment
Contraception use by men or women consistent with local regulations
Disqualifiers
Underlying physical or psychological condition prohibiting study completion
Clinically significant cardiac disease
Active or history of malignancy in the past 5 years
Serious infection within 1 month of screening
Trial design
Treatments tested in this trial
- Tazbentetol
- placebo
Treatment groups
430 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov